News
The study involves testing epcoritamab, administered subcutaneously, in combination with oral and intravenous anti-neoplastic agents. These include drugs like lenalidomide, ibrutinib, and polatuzumab ...
William Blair analysts project AbbVie to earn $16.15 per share by FY2028, a notable jump from its current $12.31 estimate.
AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...
Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...
AbbVie is testing its oral drug upadacitinib in a Phase 3 trial for patients with hidradenitis suppurativa (HS) who failed ...
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...
The study tests the combination of two drugs: Venetoclax, an oral tablet, and Azacitidine, which can be administered as an oral tablet or via subcutaneous or intravenous injection.
AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were ...
AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the ...
AbbVie beat out a competitor's migraine-fighting drug in terms of dose tolerability in a head-to-head study. The North Chicago-based drugmaker said its Phase 3 study of atogepant (Qulipta) in a ...
It is a once-daily oral CGRP receptor antagonist used to prevent episodic and chronic migraine in adults. Full results from the TEMPLE study will be presented at an upcoming medical meeting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results